Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China
Journal of Clinical Microbiology · 2025
DOI: 10.1128/jcm.01813-24 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Shanshan Yu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antitubercular Agents, Drug Resistance, Bacterial, Mycobacterium tuberculosis, Nanopore Sequencing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Capital's Funds for Health Improvement and Research, | Beijing Nova Program, Beijing Hospital Authority Ascent Plan.
Abstract (Originalsprache)
Tuberculosis (TB) management in endemic regions often grapples with resource constraints, including the scarcity of Mycobacterium tuberculosis ( M.tb ) culture laboratories. The emergence of M.tb strains with complex drug resistance profiles necessitates rapid and comprehensive drug susceptibility testing (DST) to guide patient treatment. However, traditional phenotypic DST (pDST) for M.tb is costly and time-consuming. In this study, we retrospectively enrolled 829 participants from six specialized TB treatment hospitals in China from September 2022 to July 2023. The diagnostic performance of TBseq test, a targeted-nanopore sequencing assay, was compared head-to-head with M.tb culture, acid-fast bacillus smear, quantitative polymerase chain reaction, and Xpert MTB/RIF Ultra by using clinical diagnosis as the reference standard. Subsequently, pDST for seven anti-TB drugs (rifampicin, isoniazid, ethambutol, streptomycin, levofloxacin, amikacin, and capreomycin) was performed. The resistance predictions provided by the TBseq test were compared with pDST results, which were used as a reference standard. The performance estimates of TBseq test were quantified through sensitivity, specificity, positive predictive value, negative predictive value, and the area under the receiver operating characteristic curve (AUC), providing a comprehensive assessment of its diagnostic accuracy. We found that TBseq test demonstrated significantly superior diagnostic performance for TB compared to other methods, achieving a sensitivity of 90.9% (95% CI: 88.9%–93.0%), specificity of 93.0% (95% CI: 97.2%–99.5%), and an AUC of 0.92 (95% CI: 0.876–0.963). TBseq test also exhibited robust predictive capabilities for drug resistance to the seven anti-TB drugs, with sensitivity and specificity consistently above 90% for all drugs. The AUC values ranged from 0.919 to 0.998, indicative of high diagnostic accuracy in forecasting drug resistance. IMPORTANCE Our results show that TBseq test offers excellent identification performance for tuberculosis (TB), significantly outperforming Mycobacterium tuberculosis ( M.tb) culture, acid-fast bacillus (AFB) smear, qPCR, and Xpert MTB/RIF. Its diagnostic accuracy for anti-TB drug resistance is also superior, with sensitivity and specificity above 90% for all drugs tested. This method can be integrated into routine clinical diagnostic workflows, enabling early diagnosis and reporting of drug resistance simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Beijing Tuberculosis and Thoracic Tumor Research institute, Beijing, China.
- Hebei Chest Hospital, Hebei, China.
- The Fourth People's Hospital of Nanning, Nanning, China.
- The Second Hospital of Nanjing, Nanjing, China.
- Anhui Chest Hospital, Hefei, China.
ORCID-Profile: Shanshan Yu, Qian Wang, Yunfei Wang, Liang Li, Yu Pang
Förderung
- The Capital's Funds for Health Improvement and Research
- | Beijing Nova Program
- Beijing Hospital Authority Ascent Plan
- 北京市科学技术委员会 | Beijing Nova Program
Zitieren
APA
Yu, S., Liu, N., Xie, Z., Zeng, Y., Wang, H., Wang, Q., Li, P., Li, H., Sun, J., Zhu, Q., Gao, W., Gu, H., Liu, F., Xu, P., Wang, Y., Li, L., & Pang, Y. (2025). Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01813-24
Vancouver
Yu S, Liu N, Xie Z, Zeng Y, Wang H, Wang Q, et al. Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.01813-24
BibTeX
@article{Yu2025,
author = {Yu, Shanshan and Liu, Ning and Xie, Zhouhua and Zeng, Yi and Wang, Hua and Wang, Qian and Li, Peibo and Li, Haoran and Sun, Jinhao and Zhu, Qingdong and Gao, Weiwei and Gu, Hongcang and Liu, Fuyou and Xu, Peisong and Wang, Yunfei and Li, Liang and Pang, Yu},
title = {Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China},
journal = {Journal of Clinical Microbiology},
year = {2025},
doi = {10.1128/jcm.01813-24}
}
EUVIMED